Key points: Idelalisib plus ofatumumab have a high ORR but short PFS when used for treatment-naive CLL. The short PFS is likely a result of high rates of therapy discontinuation in the setting of transaminitis, colitis, and infections.
Home / Resource Library / Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia